Baxter preps BLA on successful end to PhIII hemophilia drug study

By John Carroll Baxter International ($BAX) reports that its pivotal Phase III study comparing routine preventive use versus on-demand treatment using its anti-inhibitor coagulant ...

Medicines Co. spikes after anticlotting drug impresses in second run at PhIII

By John Carroll The Medicines Company got a big boost out of the news that its second attempt to make a great impression in a Phase III trial for its anticlotting drug cangrelor worked ...

Payer risk outrivals regulatory jitters as biggest biotech hurdle

By John Carroll Another trend we’re hearing a lot about at the J.P. Morgan confab this year is the increasingly aggressive role that payers are playing when it comes to the growing ...

Buyout buzz: Biopharma players staying focused on bolt-on deals

By John Carroll The buyout buzz in San Francisco this week has focused consistently on Big Pharma’s hefty appetite for the kind of bolt-on deals that can boost product lines ...

Biotechs choose Celgene, Novo Nordisk over pharma giants as preferred partners

By John Carroll Big Pharma companies love to hear it when new industry surveys put them at the top of the industry heap as a go-to source for new licensing deals. But a new Boston ...

Life launches genomics spinoff with Boston Children’s Hospital

By Damian Garde Life Technologies ($LIFE) is partnering with Boston Children’s Hospital to launch Claritas Genomics, a joint venture that will develop genomics-based diagnostics. The ...

LabCorp inks companion diagnostic deal with Verastem

By Damian Garde Verastem ($VSTM) has signed on with LabCorp ($LH) to validate biomarkers and develop companion diagnostics for VS-6063, the company’s in-development mesothelioma ...

JPM: TAVR surgical tool company, pain management startup grab venture cash

By Mark Hollmer Micro Interventional Devices and SPR Therapeutics are two medical device startups that just lured some crucial new venture funding, even as the market remains challenging. ...

JPM: U.S., EU regulators to mull GE’s Alzheimer’s imaging agent

By Mark Hollmer GE Healthcare ($GE) moved ever-so-close this week to the regulatory finish line for flutemetamol, a PET imaging agent designed to help diagnose Alzheimer’s disease. ...

Abbott commences massive dissolving stent trial in U.S.

By Mark Hollmer Abbott ($ABT) this week launched a massive U.S. clinical trial for its Absorb drug-eluting bioresorbable vascular scaffold, with plans to enroll up to 2,250 patients. ...

AbbVie sees no need for major acquisitions-CFO

* Pipeline includes 10 products in pivotal testing * Cash will be used for dividends, debt By Deena Beasley SAN FRANCISCO (Reuters) – AbbVie Inc, the pharmaceutical company spun ...

Ampio Stays Calm Ahead Of Further Developments

By Brian L. Wilson The last year has been very volatile for the diversified drug developer,Ampio Pharmaceuticals (NASDAQ: AMPE). AMPE was trading as low as $2.54 in May 2012 due to ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS